Active Not Recruiting NA INTERVENTIONAL 2-arm NCT06422702

The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer

A Prospective, Randomized, Single-blind Study on the Effects of Psychosomatic Symptom Interventions on Patients With Differentiated Thyroid Cancer During the Initial Treatment Period

Sponsor: Harbin Medical University

Conditions Ability to Use a Smartphone All Patients Are in the Initial Treatment Phase Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese Pathologically Confirmed Differentiated Thyroid Carcinoma Voluntary Participation in the Study and Signed Informed Consent

Interventions Extended supportive care Psychosomatic Symptoms Intervention

Updated 5 times since 2024 Last updated: Feb 14, 2025 Started: Aug 1, 2023 Primary completion: Jan 22, 2024 Completion: Apr 22, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06422702, this NA trial focuses on Ability to Use a Smartphone and All Patients Are in the Initial Treatment Phase and remains ongoing. Sponsored by Harbin Medical University, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Mar 2025 — Present [monthly]

Active Not Recruiting NA
Nov 2024 — Mar 2025 [monthly]

Active Not Recruiting NA
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting NA
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting NA

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harbin Medical University

Data source: Harbin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China